A randomised, open-label trial to assess the safety and efficacy of switching to tenofovir-emtricitabine [emtricitabine/tenofovir disoproxil fumarate] or abacavir-lamivudine [lamivudine/abacavir]: The STEAL Study.

Trial Profile

A randomised, open-label trial to assess the safety and efficacy of switching to tenofovir-emtricitabine [emtricitabine/tenofovir disoproxil fumarate] or abacavir-lamivudine [lamivudine/abacavir]: The STEAL Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/abacavir (Primary) ; HIV protease inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Indications HIV infections; HIV-1 infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms STEAL
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Aug 2011 Additional trial centre, investigator identified as reported by ClinicalTrials.gov.
    • 08 Jul 2011 New source added and integrated (Australian New Zealand Clinical Trials Registry, ACTRN012605000505606).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top